Trials / Active Not Recruiting
Active Not RecruitingNCT04238624
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to see if adding the study drug, cemiplimab, to the standard therapy with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dabrafenib | Participants will receive dabrafenib 150 mg orally twice a day |
| DRUG | Trametinib | Participants will receive trametinib 2 mg orally once a day |
Timeline
- Start date
- 2020-01-20
- Primary completion
- 2026-06-20
- Completion
- 2026-06-20
- First posted
- 2020-01-23
- Last updated
- 2025-07-02
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04238624. Inclusion in this directory is not an endorsement.